Researchers from Johns Hopkins University and affiliated organizations have published details on the discovery and preclinical characterization of a purine antimetabolite, Pro-905, which is being developed for the treatment of malignant peripheral nerve sheath tumors (MPNST).
Metastatic colorectal cancer remains the second leading cause of cancer-related mortality globally, but treatment options are generally limited to RAS mutation status for anti-EGFR therapies. Researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne developed a method to grow organoids from patient-derived tumor samples that achieved 83% accuracy in predicting patient responses to different therapies.
Researchers at Daegu-Gyeongbuk Medical Innovation Foundation and Korean Research Institute of Bioscience and Biotechnology have identified acetyl-CoA carboxylase (ACC) inhibitors reported to be useful for the treatment of liver cancer.
Synnovation Therapeutics Inc. has synthesized phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA-related overgrowth spectrum (PROS).
Researchers at Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College have disclosed pyrrolopyrimidine compounds acting as Bruton tyrosine kinase (BTK) inhibitors reported to be useful for the treatment of chronic lymphocytic leukemia, lymphoma, primary central nervous system, non-Hodgkin lymphoma, and rheumatoid arthritis.
Replay Holdings LLC has entered into an exclusive, worldwide license agreement with the National Institutes of Health (NIH) for intellectual property related to a library of T-cell receptors (TCRs) directed against multiple cancer neoantigens.
Inxmed Co. Ltd. has licensed Escugen’s Ezwi-Fit linker-payload platform for use in the development of next-generation tumor-associated antigen (TAA)-targeting antibody-drug conjugates (ADCs).
Researchers from Cogent Biosciences Inc. have reported the discovery and preclinical characterization of CGT-4255, a novel EGFR-sparing, ErbB2 inhibitor with activity against oncogenic ErbB2 mutations.
Gilead Sciences Inc. has signed an agreement with Compugen Ltd. to exclusively license Compugen’s preclinical antibody program against IL-18 binding protein, including the COM-503 drug candidate. COM-503 is a high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby inhibiting cancer growth.
Researchers from Hebei Medical University and affiliated organizations have discovered new folate receptor (FR)-targeted fluorescent probes for tumor detection.
RSS
